XML 58 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration and License Agreements - Amgen, Inc (Details)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2016
agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 43,268,000 $ 0  
Amgen Incorporated | Olpasiran Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Number of agreements | agreement     2
Contract assets 0    
Deferred revenue 0    
Amgen Incorporated | Olpasiran Agreement | Maximum      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Additional remaining development regulatory and sales milestones payments $ 485,000,000